US President Donald Trump is seen during a health care affordability event where he announced a deal with pharmaceutical company Regeneron to lower drug prices, in the Oval Office of the White House in Washington, DC, on April 23, 2026. (Photo by Brendan SMIALOWSKI / AFP via Getty Images)

...

Amanda Castro

By Amanda Castro

Associate News Editor

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


The U.S. Food and Drug Administration (FDA) said Friday it will fast‑track reviews for three psychedelic‑based treatments aimed at severe mental health conditions, marking one of the most aggressive steps yet in President Donald Trump's administration’s push to accelerate research on the drugs. The move follows an executive order signed last weekend directing federal agencies to speed studies and ease restrictions on psychedelics, which remain illegal under federal law.

Under the announcement, two psilocybin programs for treatment‑resistant depression and a methylone therapy for PTSD will receive priority review vouchers, allowing regulators to evaluate them in weeks rather than months. While the vouchers do not guarantee approval, the decision highlights the administration’s growing embrace of psychedelic medicine, a shift driven in part by veterans’ groups and political allies who have urged faster access to experimental therapies.

FDA Fast‑Tracks Psychedelic Drug Reviews After Trump Order: What to Know

The FDA said Friday it has issued priority review vouchers for two psilocybin programs targeting hard‑to‑treat depression and a third voucher for methylone, a compound related to MDMA being studied for post-traumatic stress disorder (PTSD). While the vouchers do not guarantee approval, they allow regulators to compress review timelines from months to weeks.

Read More on U.S.

The move reflects a growing political and cultural shift around psychedelics, which remain illegal under federal law but have gained support among veterans’ groups, conservative influencers, and members of the administration. FDA Commissioner Marty Makary said the agency owes it to patients “to evaluate these potential therapies with urgency,” while emphasizing that the drugs are still experimental and must be backed by rigorous evidence.

The fast‑track action is also expected to intensify scrutiny of the FDA’s National Priority Voucher program, which some lawmakers say has disproportionately benefited companies aligned with the White House.

In a separate step, the FDA has authorized early‑stage U.S. testing of noribogaine, a derivative of the psychedelic ibogaine, for alcohol use disorder—the first time a compound of its kind has been cleared for clinical study in the country. The broader push marks the most aggressive federal action on psychedelic medicine to date, accelerating a field long constrained by regulatory barriers and safety concerns.

President Donald Trump at an event in the Oval Office of the White House on April 23, 2026.

...

What the DOJ’s New Marijuana Rule Actually Does

The Justice Department has eased federal restrictions on medical marijuana, a shift officials say will make it easier for researchers and physicians to study and prescribe cannabis‑based treatments. The change moves FDA‑approved and state‑regulated medical marijuana out of Schedule I—the category reserved for drugs like heroin that are considered to have no medical use—and into Schedule III, a tier that includes substances with accepted medical applications and fewer regulatory barriers.

The move does not change the legal status of recreational marijuana, which remains a Schedule I drug under federal law. But it opens the door to expanded clinical research, simpler prescribing rules, and potentially broader access for patients. Acting Attorney General Todd Blanche said the Drug Enforcement Administration (DEA) will hold a hearing in June to consider whether recreational cannabis should also be reclassified, a step long sought by advocates and several state governments.

The decision follows an executive order signed by Trump, who directed federal agencies to accelerate efforts to reschedule marijuana after delays inside the DEA. The announcement also comes amid renewed political attention on psychedelics and other controlled substances, which the administration has pushed to study more aggressively for potential therapeutic use.

What Is Drug Scheduling?

Drug scheduling is the system the U.S. government uses to classify controlled substances based on two factors: whether they have an accepted medical use and how likely they are to be abused or cause dependence. The framework, created under the Controlled Substances Act, divides drugs into five schedules. Substances in Schedule I are considered the most tightly restricted, while those in Schedule V carry the lowest level of control.

Schedule I drugs, such as heroin, LSD and ecstasy, are defined as having no accepted medical use and a high risk of abuse. Schedules II through V include substances that have medical uses but vary in how dangerous or addictive they can be. For example, Schedule II includes medications like oxycodone and fentanyl, which are legal but tightly regulated because of their high abuse potential. Lower schedules cover drugs with decreasing risk, down to Schedule V products like certain cough syrups that contain small amounts of codeine.

The scheduling system also covers analogs, substances that aren’t specifically listed but are chemically or pharmacologically similar to Schedule I or II drugs. These can be treated as Schedule I for criminal prosecution if they’re intended for human consumption. The lists themselves aren’t exhaustive, but they serve as the federal government’s guide for regulating, prescribing and enforcing laws around controlled substances.

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines